Page 50 - TD-4-3

Tumor Discovery HRD genomic alterations in Chinese NSCLC

Funding Biol Med. 2020;17(2):444-457.

This study was jointly funded by the Wanzhou District doi: 10.20892/j.issn.2095-3941.2019.0363
Science and Technology Bureau of Chongqing (Grant 4. Khaddour K, Felipe Fernandez M, Khabibov M, et al. The
No.: wzstc-kw2022029) and the Wanzhou District Health prognostic and therapeutic potential of DNA damage
Commission of Chongqing (Grant No. wzstc-kw2022029). repair pathway alterations and homologous recombination
deficiency in lung cancer. Cancers (Basel). 2022;14(21):5305.
Conflict of interest
doi: 10.3390/cancers14215305
Mingzhu Yin is an Editor-in-Chief of this journal but was 5. Li Z, Su W, Bai B, et al. Single-cell sequencing for lung
not in any way involved in the editorial and peer-review cancer research: Progress and prospects. Eur J Med Oncol.
process conducted for this paper, directly or indirectly. 2025:6883.
Separately, other authors declared that they have no known
competing financial interests or personal relationships that doi: 10.36922/ejmo.6883
could have influenced the work reported in this paper. 6. Karacin C, Eren T, Imamoglu GI, et al. The relationship
between primary tumor localization and driver mutation in
Author contributions lung cancer. Eur J Med Oncol. 2020;4(3):215-218.

Conceptualization: Shuang Xiang, Song Duan, Mingzhu Yin doi: 10.14744/ejmo.2020.13543
Formal analysis: Yi Liu 7. Bittoni M, Yang JC, Shih JY, et al. Real-world insights into
Investigation: Chun Huang, Ya-ting Yang patients with advanced NSCLC and MET alterations. Lung
Methodology: Jing Guo Cancer. 2021;159:96-106.
Writing – original draft: Shuang Xiang, Changqiong Shen doi: 10.1016/j.lungcan.2021.06.015
Writing – review & editing: Song Duan, Mingzhu Yin
8. Huang Q, Li F, Hu H, et al. Loss of TSC1/TSC2 sensitizes
Ethics approval and consent to participate immune checkpoint blockade in non-small cell lung cancer.
Sci Adv. 2022;8(5):eabi9533.
The study was approved by the Research Ethics
Committee of the Chongqing University Three Gorges doi: 10.1126/sciadv.abi9533
Hospital (Institutional Review Board approval number: 9. Matsuzaki K, Kondo S, Ishikawa T, Shinohara A. Human
2022-Scientific Research No. 145). Written informed RAD51 paralogue SWSAP1 fosters RAD51 filament by
consent was obtained from the patients before their regulating the anti-recombinase FIGNL1 AAA+ ATPase.
participation. Nat Commun. 2019;10(1):1407.

Consent for publication doi: 10.1038/s41467-019-09190-1
10. Bukhari AB, Lewis CW, Pearce JJ, Luong D, Chan GK,
Patients consented on the publication of their data. Gamper AM. Inhibiting Wee1 and ATR kinases produces
Availability of data tumor-selective synthetic lethality and suppresses metastasis.
J Clin Invest. 2019;129(3):1329-1344.
The sequencing data were obtained from the public doi: 10.1172/JCI122622
datasets of TCGA and affiliated research centers.
11. Turdo A, Gaggianesi M, Di Franco S, et al. Effective targeting
References of breast cancer stem cells by combined inhibition of Sam68
and Rad51. Oncogene. 2022;41(15):2196-2209.
1. Zhao Z, Du L, Wang L, Wang Y, Yang Y, Dong H. Preferred
lung cancer screening modalities in China: A discrete choice doi: 10.1038/s41388-022-02239-4
experiment. Cancers (Basel). 2021;13(23):6110. 12. Peng G, Chun-Jen Lin C, Mo W, et al. Genome-wide
doi: 10.3390/cancers13236110 transcriptome profiling of homologous recombination DNA
repair. Nat Commun. 2014;5:3361.
2. Yang J, Hao R, Zhang Y, Deng H, Teng W, Wang Z.
Construction of circRNA-miRNA-mRNA network and doi: 10.1038/ncomms4361
identification of novel potential biomarkers for non-small 13. Pratz KW, Rudek MA, Gojo I, et al. A phase I study of
cell lung cancer. Cancer Cell Int. 2021;21(1):611. topotecan, carboplatin and the PARP inhibitor veliparib in
doi: 10.1186/s12935-021-02278-z acute leukemias, aggressive myeloproliferative neoplasms,
and chronic myelomonocytic leukemia. Clin Cancer Res.
3. Moreno-Rubio J, Ponce S, Álvarez R, et al. Clinical-
pathological and molecular characterization of long-term 2017;23(4):899-907.
survivors with advanced non-small cell lung cancer. Cancer doi: 10.1158/1078-0432.CCR-16-1274

Volume 4 Issue 3 (2025) 42 doi: 10.36922/TD025180032